文献速递胸部肿瘤

可根治性切除的Ⅰ至ⅢA期EGFR突变非小细胞肺癌患者血浆循环肿瘤DNA的纵向监测

Longitudinal Monitoring of Circulating Tumor DNA From Plasma in Patients With Curative Resected Stages I to IIIA EGFR-Mutant Non-Small Cell Lung Cancer.
PubMed 文献 · J Thorac Oncol · 2023-06-10

该研究纳入278例可根治性切除的Ⅰ至ⅢA期EGFR突变非小细胞肺癌患者,纵向监测血浆循环肿瘤DNA(ctDNA)。基线ctDNA阳性且术后微小残留病(MRD)阳性组3年无病生存率(DFS)为50%,低于基线ctDNA阴性组的84%和基线ctDNA阳性但术后MRD阴性组的78%(p=0.02)。纵向监测ctDNA可能在影像学复发前检测到早期复发。

要点

  • 基线ctDNA阳性且术后MRD阳性患者3年DFS率为50%,低于基线ctDNA阴性组的84%和术后MRD阴性组的78%(p=0.02)。
  • 调整临床病理变量后,ctDNA仍是DFS的独立危险因素(p<0.001),分期(p<0.001)和微乳头亚型(p=0.02)也是独立危险因素。
  • 纵向监测ctDNA在69%的19外显子缺失患者和20%的L858R突变患者中于影像学复发前检测到MRD。

核心结论

  • 基线ctDNA阳性或MRD阳性状态与可根治性切除的Ⅰ至ⅢA期EGFR突变非小细胞肺癌患者较差的DFS相关。
  • 纵向监测ctDNA作为一种非侵入性方法,可能有助于在影像学复发前检测早期复发。

研究设计与样本

  • 研究于2015年8月至2017年10月纳入278例可根治性切除的Ⅰ至ⅢA期(美国癌症联合委员会第七版)常见EGFR突变非小细胞肺癌患者。
  • 采用微滴数字聚合酶链反应纵向监测ctDNA,时间点包括基线(术前)、根治性手术后4周及按方案随访至5年,并配合影像学随访。
  • 主要结局为根据标志性时间点ctDNA阳性状态分组的无病生存期(DFS)以及纵向监测ctDNA的敏感性。

主要发现

  • 278例患者中,67例(24%)术前基线ctDNA可检测到:ⅠA期23%、ⅠB期18%、ⅡA期18%、ⅡB期50%、ⅢA期42%(p=0.06)。
  • 基线ctDNA阳性的67例患者中,76%(51/67)在术后4周清除(术后)。
  • 患者分为三组:A组基线ctDNA阴性(n=211)、B组基线ctDNA阳性但术后MRD阴性(n=51)、C组基线ctDNA阳性且术后MRD阳性(n=16)。
  • 3年DFS率三组间有显著差异:A组84%、B组78%、C组50%(p=0.02)。
  • 调整临床病理变量后,ctDNA仍是DFS的独立危险因素(p<0.001),分期(p<0.001)和微乳头亚型(p=0.02)也是独立危险因素。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: For patients with early stage EGFR-mutant-positive (EGFR-M+) NSCLC, curative surgery followed by adjuvant chemotherapy is considered the standard of care. This study evaluated the feasibility and efficacy of longitudinal monitoring of circulating tumor DNA (ctDNA) as a valuable biomarker for early detection of minimal residual disease (MRD) and provides identification of the group at high risk for recurrence in resected stages I to IIIA EGFR-M+ NSCLC. METHODS: Between August 2015 and October 2017, a total of 278 patients with curative resected, stages I to IIIA (American Joint Committee on Cancer seventh version) common EGFR-M+ NSCLC were analyzed. Radiological follow-up was accompanied with longitudinal monitoring of ctDNA using a droplet-digital polymerase chain reaction from baseline (preoperative), 4 weeks after curative surgery, and follow-up per protocol until 5 years. The primary outcomes were disease-free survival (DFS) according to the status of ctDNA positivity at landmark points and the sensitivity of longitudinal monitoring of ctDNA. RESULTS: Among 278 patients, preoperative baseline ctDNA was detected in 67 (24%) patients: 23% (stage IA), 18% (IB), 18% (IIA), 50% (IIB), and 42% (IIIA) (p = 0.06). Of patients with baseline ctDNA, 76% (51 of 67) had clearance at 4 weeks after surgery (postoperative). Patients were classified into the following three groups; group A, baseline ctDNA negative (n = 211) versus group B, baseline ctDNA positive but postoperative MRD negative (n = 51) versus group C, baseline ctDNA positive and postoperative MRD positive (n = 16). The 3-year DFS rate was significantly different among the three groups (84% for group A, 78% for group B, and 50% for group C, p = 0.02). After adjusting for clinicopathologic variables, ctDNA still remains an independent risk factor for DFS along with stage (p < 0.001) and micropapillary subtype (p = 0.02). With longitudinal monitoring of ctDNA, MRD was detected before radiological recurrence in 69% of patients with exon 19 deletion and in 20% with L858R mutation. CONCLUSIONS: These results suggest that patients with baseline ctDNA-positive or MRD-positive status were associated with poor DFS in curative resected stages I to IIIA EGFR-M+ NSCLC and that longitudinal monitoring of ctDNA, a noninvasive method, might be useful to detect early recurrence before radiological recurrence.

来源:J Thorac Oncol,查看原文。版权归原作者所有。

引用

  1. Jung HA, Ku BM, Kim YJ, et al. Longitudinal Monitoring of Circulating Tumor DNA From Plasma in Patients With Curative Resected Stages I to IIIA EGFR-Mutant Non-Small Cell Lung Cancer. J Thorac Oncol. 2023. PMID: 37308037. doi:10.1016/j.jtho.2023.05.027

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。